Christine M Tarby

US Patent:

6410566, Jun 25, 2002

Filed:

Jul 16, 2001

Appl. No.:

09/905077

Inventors:

Tatsuki Shiota - Hino, JP
Ken-ichiro Kataoka - Hino, JP
Minoru Imai - Hino, JP
Takaharu Tsutsumi - Hino, JP
Masaki Sudoh - Handa, JP
Ryo Sogawa - Hino, JP
Takuya Morita - Hino, JP
Takahiko Hada - Okayama, JP
Yumiko Muroga - Hino, JP
Osami Takenouchi - Hino, JP
Minoru Furuya - Hino, JP
Noriaki Endo - Hino, JP
Christine M. Tarby - Hockessin DE
Wilna Moree - San Diego CA
Steven Teig - Palo Alto CA

Assignee:

Teijin Limited - Osaka
Dupont Phamaceuticals Company - San Diego CA

International Classification:

A01N 4340

US Classification:

514329, 546224, 546234, 546233, 546207, 546196, 546194, 514318, 514320, 514326, 514331

US Patent:

6451842, Sep 17, 2002

Filed:

May 16, 2000

Appl. No.:

09/554562

Inventors:

Tatsuki Shiota - Hino, JP
Ken-ichiro Kataoka - Hino, JP
Minoru Imai - Hino, JP
Takaharu Tsutsumi - Hino, JP
Masaki Sudoh - Handa, JP
Ryo Sogawa - Hino, JP
Takuya Morita - Hino, JP
Takahiko Hada - Okayama, JP
Yumiko Muroga - Hino, JP
Osami Takenouchi - Hino, JP
Minoru Furuya - Hino, JP
Noriaki Endo - Hino, JP
Christine M. Tarby - Hockessin DE
Wilna Moree - San Diego CA
Steven Teig - Sunnyvale CA

Assignee:

Dupont Pharmaceuticals Company - San Diego CA
Teijin Limited - Osaka

International Classification:

A61K 314025

US Classification:

514422, 548527, 548525, 548517, 548217, 548557, 514426

US Patent:

6479492, Nov 12, 2002

Filed:

Jan 21, 2000

Appl. No.:

09/489378

Inventors:

Andrei W. Konradi - San Francisco CA
Michael A. Pleiss - Sunnyvale CA
Eugene D. Thorsett - Half Moon Bay CA
Susan Ashwell - Plainsboro NJ
Dimitrios Sarantakis - Newtown PA
Gregory S. Welmaker - Jackson NJ
Anthony Kreft - Langhorne PA
Christopher Semko - Fremont CA
Robert Warren Sullivan - Oceanside CA
Christopher Joseph Soares - La Jolla CA
Kiev Sui Ly - San Diego CA
Christine M. Tarby - Hockessin DE

Assignee:

Elan Pharmaceuticals, Inc. - So. San Francisco CA

International Classification:

A61K 3153

US Classification:

514241, 514245, 544180, 544194, 544204, 544217, 544220

Abstract:

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimers disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

US Patent:

6593337, Jul 15, 2003

Filed:

Oct 18, 2000

Appl. No.:

09/691249

Inventors:

Barry L. Johnson - Wilmington DE
Mona Patel - Bridgewater NJ
James D. Rodgers - Landenberg PA
Christine M. Tarby - Hockessin DE
Rajagopal Bakthavatchalam - Wilmington DE

Assignee:

Bristol-Myers Squibb Pharma Company - Princeton NJ

International Classification:

C07D47104

US Classification:

514293, 546 81

Abstract:

The present invention relates to tricyclic compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

US Patent:

6686353, Feb 3, 2004

Filed:

Jul 15, 1999

Appl. No.:

09/180994

Inventors:

Tatsuki Shiota - Kanagawa, JP
Shinsuke Yamagami - Tokyo, JP
Kenichiro Kataoka - Tokyo, JP
Noriaki Endo - Tokyo, JP
Hiroko Tanaka - Tokyo, JP
Doug Barnum - San Francisco CA
Jonathan Greene - Palo Alto CA
Wilna Moree - San Diego CA
Michele Ramirez Weinhouse - Escondido CA
Christine M. Tarby - Cardiff CA

Assignee:

Teijin Intellectual Property Center Limited - Osaka
Combichem, Inc. - CA

International Classification:

A61K 3155

US Classification:

514218, 51425213, 51425504, 51425301, 540575, 544359, 544398, 544403, 544360, 544379, 544396

Abstract:

Cyclic diamines of formula (I) or their pharmacologically acceptable acid addition salts, and their medical applications are described. These compounds inhibit the action of chemokines such as MIP-1a and/or MCP-1 on target cells, and are useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissue.

US Patent:

6844340, Jan 18, 2005

Filed:

Jan 17, 2003

Appl. No.:

10/346613

Inventors:

Christine M. Tarby - Hockessin DE, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D47104
C07D47114
C07D48704
A61K 3153
A61P 3118

US Classification:

514248, 514267, 544234, 544249, 544250, 544251

Abstract:

The present invention relates to tricyclic 2-pyrimidone compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

US Patent:

7125895, Oct 24, 2006

Filed:

May 12, 2000

Appl. No.:

09/569766

Inventors:

Christine M. Tarby - Hockessin DE, US
Wilna Moree - San Diego CA, US

Assignee:

Bristol-Myers Squibb Pharma Research Labs, Inc. - Princeton NJ

International Classification:

A61K 31/4525
A61K 31/4535
C07D 211/32
C07D 401/12
C07D 405/12

US Classification:

514315, 514323, 514326, 546201, 546213, 546214, 546245

Abstract:

This invention relates to novel arylalkyl cyclic amine derivatives. This invention also relates to chemokine receptor antagonists that are be effective as therapeutic agents and/or preventive agents for diseases such as atherosclerosis, rheumatoid arthritis, transplant rejection, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis, and myocarditis, in which tissue infiltration of blood monocytes and lymphocytes plays a major role in the initiation, progression or maintenance of the disease. Furthermore, chemokine receptor antagonists also inhibit the interaction of viruses, which attack blood monocytes and lymphocytes, through the use of a chemokine receptor. One such example is the HIV virus.

US Patent:

7186830, Mar 6, 2007

Filed:

Jul 15, 2004

Appl. No.:

10/891974

Inventors:

Christine M. Tarby - Hockessin DE, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 239/00
A01N 43/54

US Classification:

544250, 514267

Abstract:

The present invention relates to tricyclic 2-pyrimidone compounds of formula (I):.